Literature DB >> 33563917

IL-33-induced neutrophil extracellular traps degrade fibronectin in a murine model of bronchopulmonary dysplasia.

Rui Jin1, Junjie Xu1, Qianqian Gao1, Xiaonan Mao1, Jiao Yin1, Keyu Lu1, Yan Guo1, Mingshun Zhang2, Rui Cheng3.   

Abstract

Bronchopulmonary dysplasia (BPD) is the leading cause of chronic lung disease in preterm neonates. Extracellular matrix (ECM) abnormalities reshape lung development, contributing to BPD progression. In the present study, we first discovered that the ECM component fibronectin was reduced in the pulmonary tissues of model mice with BPD induced by lipopolysaccharide (LPS) and hyper-oxygen. Meanwhile, interleukin-33 (IL-33) and other inflammatory cytokines were elevated in BPD lung tissues. LPS stimulated the production of IL-33 in alveolar epithelial cells via myeloid differentiation factor 88 (MyD88), protein 38 (p38), and nuclear factor-kappa B (NF-κB) protein 65 (p65). Following the knockout of either IL-33 or its receptor suppression of tumorigenicity 2 (ST2) in mice, BPD disease severity was improved, accompanied by elevated fibronectin. ST2 neutralization antibody also relieved BPD progression and restored the expression of fibronectin. IL-33 induced the formation of neutrophil extracellular traps (NETs), which degraded fibronectin in alveolar epithelial cells. Moreover, DNase-mediated degradation of NETs was protective against BPD. Finally, a fibronectin inhibitor directly decreased fibronectin and caused BPD-like disease in the mouse model. Our findings may shed light on the roles of IL-33-induced NETs and reduced fibronectin in the pathogenesis of BPD.

Year:  2020        PMID: 33563917     DOI: 10.1038/s41420-020-0267-2

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN: 2058-7716


  43 in total

1.  Recombinant fibronectin matrix mimetics specify integrin adhesion and extracellular matrix assembly.

Authors:  Daniel C Roy; Denise C Hocking
Journal:  Tissue Eng Part A       Date:  2012-11-01       Impact factor: 3.845

Review 2.  Epidemiology of bronchopulmonary dysplasia.

Authors:  Erik A Jensen; Barbara Schmidt
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03-17

Review 3.  IL-33 in T Cell Differentiation, Function, and Immune Homeostasis.

Authors:  Michael Peine; Roman M Marek; Max Löhning
Journal:  Trends Immunol       Date:  2016-04-04       Impact factor: 16.687

4.  Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion.

Authors:  Irina G Luzina; Edward M Pickering; Pavel Kopach; Phillip H Kang; Virginia Lockatell; Nevins W Todd; John C Papadimitriou; Andrew N J McKenzie; Sergei P Atamas
Journal:  J Immunol       Date:  2012-05-25       Impact factor: 5.422

Review 5.  Fibronectin and fibronectin receptors in lung development.

Authors:  J Roman
Journal:  Exp Lung Res       Date:  1997 Mar-Apr       Impact factor: 2.459

6.  Fibronectin expression in bronchopulmonary dysplasia.

Authors:  R A Sinkin; M Roberts; M B LoMonaco; R J Sanders; L A Metlay
Journal:  Pediatr Dev Pathol       Date:  1998 Nov-Dec

Review 7.  Fibronectin: role in respiratory distress syndrome and bronchopulmonary dysplasia.

Authors:  C L Watts; A A Fanaroff
Journal:  Semin Perinatol       Date:  1992-06       Impact factor: 3.300

Review 8.  Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family.

Authors:  Corinne Cayrol; Jean-Philippe Girard
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

9.  Changes in lung tissue fibronectin content and synthesis during postnatal lung growth.

Authors:  D J Plumb; B A Dubaybo; L A Thet
Journal:  Pediatr Pulmonol       Date:  1987 Nov-Dec

10.  Blockade of IL-33 release and suppression of type 2 innate lymphoid cell responses by helminth secreted products in airway allergy.

Authors:  H J McSorley; N F Blair; K A Smith; A N J McKenzie; R M Maizels
Journal:  Mucosal Immunol       Date:  2014-02-05       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.